Cargando…

Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain

BACKGROUND: Engaging the endocannabinoid system through inhibition of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), degrading endocannabinoids (endoCBs) 2-arachidonoylglycerol (2-AG) and anandamide (AEA), was proposed as a promising approach to ameliorate migraine pain. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Pietra, Adriana, Krivoshein, Georgii, Ivanov, Konstantin, Giniatullina, Raisa, Jyrkkänen, Henna-Kaisa, Leinonen, Ville, Lehtonen, Marko, van den Maagdenberg, Arn M. J. M., Savinainen, Juha, Giniatullin, Rashid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088116/
https://www.ncbi.nlm.nih.gov/pubmed/37038131
http://dx.doi.org/10.1186/s10194-023-01568-3
_version_ 1785022499900096512
author Della Pietra, Adriana
Krivoshein, Georgii
Ivanov, Konstantin
Giniatullina, Raisa
Jyrkkänen, Henna-Kaisa
Leinonen, Ville
Lehtonen, Marko
van den Maagdenberg, Arn M. J. M.
Savinainen, Juha
Giniatullin, Rashid
author_facet Della Pietra, Adriana
Krivoshein, Georgii
Ivanov, Konstantin
Giniatullina, Raisa
Jyrkkänen, Henna-Kaisa
Leinonen, Ville
Lehtonen, Marko
van den Maagdenberg, Arn M. J. M.
Savinainen, Juha
Giniatullin, Rashid
author_sort Della Pietra, Adriana
collection PubMed
description BACKGROUND: Engaging the endocannabinoid system through inhibition of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), degrading endocannabinoids (endoCBs) 2-arachidonoylglycerol (2-AG) and anandamide (AEA), was proposed as a promising approach to ameliorate migraine pain. However, the activity of MAGL and FAAH and action of endoCB on spiking activity of meningeal afferents, from which migraine pain originates, has not been explored thus far. Therefore, we here explored the analgesic effects of endoCB enhancement in rat and human meningeal tissues. METHODS: Both MAGL and FAAH activity and local 2-AG and AEA levels were measured by activity-based protein profiling (ABPP) and LC–MS/MS, respectively, in rat meninges obtained from hemiskulls of P38-P40 Wistar rats and human meninges from elderly patients undergoing non-migraine related neurosurgery. The action on endoCBs upon administration of novel dual MAGL/FAAH inhibitor AKU-005 on meningeal afferents excitability was tested by investigating paired KCl-induced spiking and validation with local (co-)application of either AEA or 2-AG. Finally, the specific TRPV1 agonist capsaicin and blocker capsazepine were tested. RESULTS: The basal level of 2-AG exceeded that of AEA in rat and human meninges. KCl-induced depolarization doubled the level of AEA. AKU-005 slightly increased spontaneous spiking activity whereas the dual MAGL/FAAH inhibitor significantly decreased excitation of nerve fibres induced by KCl. Similar inhibitory effects on meningeal afferents were observed with local applications of 2-AG or AEA. The action of AKU-005 was reversed by CB1 antagonist AM-251, implying CB1 receptor involvement in the anti-nociceptive effect. The inhibitory action of AEA was also reversed by AM-251, but not with the TRPV1 antagonist capsazepine. Data cluster analysis revealed that both AKU-005 and AEA largely increased long-term depression-like meningeal spiking activity upon paired KCl-induced spiking. CONCLUSIONS: In the meninges, high anti-nociceptive 2-AG levels can tonically counteract meningeal signalling, whereas AEA can be engaged on demand by local depolarization. AEA-mediated anti-nociceptive effects through CB1 receptors have therapeutic potential. Together with previously detected MAGL activity in trigeminal ganglia, dual MAGL/FAAH inhibitor AKU-005 appears promising as migraine treatment. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01568-3.
format Online
Article
Text
id pubmed-10088116
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-100881162023-04-12 Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain Della Pietra, Adriana Krivoshein, Georgii Ivanov, Konstantin Giniatullina, Raisa Jyrkkänen, Henna-Kaisa Leinonen, Ville Lehtonen, Marko van den Maagdenberg, Arn M. J. M. Savinainen, Juha Giniatullin, Rashid J Headache Pain Research BACKGROUND: Engaging the endocannabinoid system through inhibition of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), degrading endocannabinoids (endoCBs) 2-arachidonoylglycerol (2-AG) and anandamide (AEA), was proposed as a promising approach to ameliorate migraine pain. However, the activity of MAGL and FAAH and action of endoCB on spiking activity of meningeal afferents, from which migraine pain originates, has not been explored thus far. Therefore, we here explored the analgesic effects of endoCB enhancement in rat and human meningeal tissues. METHODS: Both MAGL and FAAH activity and local 2-AG and AEA levels were measured by activity-based protein profiling (ABPP) and LC–MS/MS, respectively, in rat meninges obtained from hemiskulls of P38-P40 Wistar rats and human meninges from elderly patients undergoing non-migraine related neurosurgery. The action on endoCBs upon administration of novel dual MAGL/FAAH inhibitor AKU-005 on meningeal afferents excitability was tested by investigating paired KCl-induced spiking and validation with local (co-)application of either AEA or 2-AG. Finally, the specific TRPV1 agonist capsaicin and blocker capsazepine were tested. RESULTS: The basal level of 2-AG exceeded that of AEA in rat and human meninges. KCl-induced depolarization doubled the level of AEA. AKU-005 slightly increased spontaneous spiking activity whereas the dual MAGL/FAAH inhibitor significantly decreased excitation of nerve fibres induced by KCl. Similar inhibitory effects on meningeal afferents were observed with local applications of 2-AG or AEA. The action of AKU-005 was reversed by CB1 antagonist AM-251, implying CB1 receptor involvement in the anti-nociceptive effect. The inhibitory action of AEA was also reversed by AM-251, but not with the TRPV1 antagonist capsazepine. Data cluster analysis revealed that both AKU-005 and AEA largely increased long-term depression-like meningeal spiking activity upon paired KCl-induced spiking. CONCLUSIONS: In the meninges, high anti-nociceptive 2-AG levels can tonically counteract meningeal signalling, whereas AEA can be engaged on demand by local depolarization. AEA-mediated anti-nociceptive effects through CB1 receptors have therapeutic potential. Together with previously detected MAGL activity in trigeminal ganglia, dual MAGL/FAAH inhibitor AKU-005 appears promising as migraine treatment. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01568-3. Springer Milan 2023-04-11 /pmc/articles/PMC10088116/ /pubmed/37038131 http://dx.doi.org/10.1186/s10194-023-01568-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Della Pietra, Adriana
Krivoshein, Georgii
Ivanov, Konstantin
Giniatullina, Raisa
Jyrkkänen, Henna-Kaisa
Leinonen, Ville
Lehtonen, Marko
van den Maagdenberg, Arn M. J. M.
Savinainen, Juha
Giniatullin, Rashid
Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
title Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
title_full Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
title_fullStr Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
title_full_unstemmed Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
title_short Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
title_sort potent dual magl/faah inhibitor aku-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088116/
https://www.ncbi.nlm.nih.gov/pubmed/37038131
http://dx.doi.org/10.1186/s10194-023-01568-3
work_keys_str_mv AT dellapietraadriana potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT krivosheingeorgii potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT ivanovkonstantin potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT giniatullinaraisa potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT jyrkkanenhennakaisa potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT leinonenville potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT lehtonenmarko potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT vandenmaagdenbergarnmjm potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT savinainenjuha potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain
AT giniatullinrashid potentdualmaglfaahinhibitoraku005engagesendocannabinoidstodiminishmeningealnociceptionimplicatedinmigrainepain